Novel oral vaccine using genetically engineering bifidobacterium displaying antigen on its cell-surface
| Project/Area Number |
20591201
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Infectious disease medicine
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
SHIRAKAWA Toshiro Kobe University, 大学院・保健学研究科, 准教授 (70335446)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SHIMADA Masaru 横浜市立大学, 大学院・医学研究科, 准教授 (40301452)
KATAYAMA Tkakane 石川県立大学, 生物資源工学研究所, 准教授 (70346104)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | ワクチン / 腸チフス / 粘膜免疫 / ビフィズス菌 |
|---|
| Research Abstract |
Genetically modified probiotic bacteria show promise as an antigen delivery vehicle for mucosal immunization. We developed a novel vaccine platform utilizing Bifidobacterium as an antigen delivery vehicle for mucosal immunization. Genetically modified Bifidobacterium longum displaying Salmonella-flagellin on the cell surface was constructed for the oral typhoid vaccine. We confirmed the efficacy of this oral vaccine in a murine typhoid fever model.
|
Report
(4 results)
Research Products
(7 results)
